Imaging Changes in Synaptic Acetylcholine Availability in Living Human Subjects

Irina Esterlis[1], Jonas O. Hannestad[1], Frederic Bois[1,2], R. Andrew Sewell[1], Rachel F. Tyndale[3], John P. Seibyl[4], Marina R. Picciotto[1], Marc Laruelle[1], Richard E. Carson[2], and Kelly P. Cosgrove[1,2]

[1]Department of Psychiatry, Yale University, New Haven, Connecticut; [2]Department of Radiology, Yale University, New Haven, Connecticut; [3]Department of Pharmacology and Toxicology and Department of Psychiatry, CAMH and University of Toronto, Toronto, Ontario, Canada; and [4]Institute for Neurodegenerative Disorders, New Haven, Connecticut

In vivo estimation of β_2-nicotinic acetylcholine receptor availability with molecular neuroimaging is complicated by competition between the endogenous neurotransmitter acetylcholine and the radioligand ^{123}I-3-[2(S)-2-azetidinylmethoxy]pyridine (^{123}I-5-IA). We examined whether binding of ^{123}I-5-IA is sensitive to increases in extracellular levels of acetylcholine in humans, as suggested in nonhuman primates. **Methods:** Six healthy subjects (31 ± 4 y) participated in a ^{123}I-5-IA SPECT study. After baseline scans, physostigmine (1–1.5 mg) was administered intravenously over 60 min, and 9 additional scans were obtained. **Results:** We observed a significant reduction in the total volume of distribution after physostigmine administration (29% ± 17% in the cortex, 19% ± 15% in the thalamus, 19% ± 15% in the striatum, and 36% ± 30% in the cerebellum; $P < 0.05$). This reduction reflected a combination of a region-specific 7%–16% decrease in tissue concentration of tracer and a 9% increase in plasma parent concentration. **Conclusion:** These data suggest that increases in acetylcholine compete with ^{123}I-5-IA for binding to β_2-nicotinic acetylcholine receptor. Additional validation of this paradigm is warranted, but it may be used to interrogate changes in extracellular acetylcholine.

Key Words: brain β_2*-nAChRs; ^{123}I-5-IA SPECT; physostigmine; extracellular acetylcholine

In vivo molecular imaging studies of muscarinic and nicotinic acetylcholine receptors have provided substantial contributions to our understanding of disorders related to cholinergic dysfunction but are limited by the lack of a suitable method for measuring fluctuations in brain acetylcholine levels. For example, our evaluation of the β_2-nicotinic acetylcholine receptor (β_2*-nAChR) demonstrated significantly lower receptor availability in unmedicated individuals with major depressive disorder than in control subjects (1); however, quantitation of total β_2*-nAChR binding sites in postmortem brain revealed no differences between major depressive disorder and control samples, suggesting that increased acetylcholine levels in vivo may have resulted in lower β_2*-nAChR availability and apparent lower receptor density.

In vivo imaging of β_2*-nAChRs is possible with the high-affinity radioligand ^{123}I-3-[2(S)-2-azetidinylmethoxy]pyridine (^{123}I-5-IA) (2) and SPECT (3). ^{123}I-5-IA has slow dissociation from the receptor–ligand complex, a good specific-to-nonspecific binding ratio, and high selectivity for β_2*-nAChRs (3,4). ^{123}I-5-IA has been used to measure β_2*-nAChR availability in animals (4–6) and humans (7,8); however, there are no published studies demonstrating in vivo measurements of brain levels of acetylcholine in human subjects. Studies on nonhuman primates suggest that competition between acetylcholine and radioligand may be detectable (9,10), and microdialysis studies on rodents suggest an at least 10- to 30-fold increase (depending on dose) in brain acetylcholine levels after acetylcholinesterase inhibitor administration (11). In one study, ^{123}I-5-IA binding in the thalamus was decreased (15%) after a challenge with a 0.067 mg/kg dose of physostigmine and was consistently decreased (14%–17%) after a challenge with a 0.2 mg/kg dose (10).

Here, we used ^{123}I-5-IA SPECT to determine whether physostigmine-induced increases in extracellular acetylcholine in the brain compete with ^{123}I-5-IA binding in vivo in humans. We hypothesized that physostigmine-induced increases in extracellular acetylcholine would significantly reduce ^{123}I-5-IA binding.

MATERIALS AND METHODS

Six healthy control subjects (3 men and 3 women; mean age ± SD, 31 ± 4 y) gave written informed consent and completed the study, which was approved by the institutional review boards of Yale University School of Medicine, Veterans Affairs Health Care System, and the University of Toronto. Eligibility was evaluated via a structured interview, behavioral assessments, physical examination, laboratory blood tests, urine drug screening, and an electrocardiogram. Subjects had never smoked; had no life-time psychiatric, neurologic, or medical history; and had no contraindications for undergoing an MRI scan and a ^{123}I-5-IA SPECT scan on the same day.

Mood symptoms were measured with the Center for Epidemiological Studies Depression Scale (12) and the Beck Depression Inventory (13). State and trait anxiety symptoms were measured

with the Spielberger State-Trait Anxiety Inventory (*14*). All tests were administered at intake and on the scanning day (before and after physostigmine administration).

MRI was performed on a 3-T Magnetom Trio with Tim technology (Siemens) running Numaris/4 software (version: syngo MR B17) to guide placement of regions of interest for SPECT scans (series 1: 3-plane localizer; series 2: sagittal 3-dimensional turbo fast low-angle shot, 250-mm field of view, 1-mm-thick slices, 176 slices in total, echo time of 3.53 ms, repetition time of 2,500 ms, inversion time of 1,100 ms, flip angle of 7, 256 × 256 matrix, and 2 signal averages).

^{123}I-5-IA was synthesized and administered for the duration of the study as described previously (*7*) using a bolus plus a constant infusion (7.3 ± 0.2 h) with a total injected dose (accounting for decay) of 390.2 ± 13.2 MBq. Six hours after injection of ^{123}I-5-IA, a simultaneous transmission emission scan and 3 equilibrium 30-min emission scans (90 min total) were obtained on a Prism 3000 XP SPECT camera (Phillips). Subjects were administered glycopyrrolate (0.2 mg, intravenously) to minimize peripheral muscarinic side effects, followed by administration of physostigmine (a reversible acetylcholinesterase inhibitor that crosses the blood–brain barrier) over 1 h (1–1.5 mg, intravenously). Thereafter, up to 3 sets of 30-min emission scans were acquired (each set 90 min in duration, with a 20- to 30-min break between each set. In subject 5, the ^{123}I-5-IA infusion was interrupted after the collection of 5 postphysostigmine scans; thus, data thereafter are not shown. In the other 5 subjects, all 9 postphysostigmine scans were collected). Venous blood samples were collected before and after physostigmine administration to correct for individual differences in radiotracer metabolism and protein binding. Pulse and blood pressure were measured before and after injection of ^{123}I-5-IA and before and after physostigmine administration.

SPECT images were analyzed as described previously (*7*). Regional ^{123}I-5-IA uptake (β_2*-nAChR availability) was calculated as total volume of distribution (V_T/f_p), where V_T is brain regional activity divided by metabolite-corrected plasma activity and f_p is the free fraction of parent in plasma. Plasma for f_p calculation was collected at 4 time points and applied to calculate the corresponding V_T/f_p. The first was before ^{123}I-5-IA administration (baseline), the second was immediately before physostigmine administration, the third was immediately after physostigmine administration, and the fourth was at the end of the last set of postdrug scans. Specifically, f_p values from time points 1 and 2 were averaged and applied to baseline V_T to estimate baseline V_T/f_p; f_p from time point 3 (immediately after physostigmine administration) was applied to V_T from the first and second postphysostigmine scanning sessions to estimate V_T/f_p for those time points; and f_p from time point 4 was applied to the last scanning session. The regions studied were frontal, parietal, anterior cingulate, temporal, and occipital cortices (averaged to obtained a single cortical value); striatum; thalamus; and cerebellum. The change in radioligand binding to β_2*-nAChRs was calculated as the percentage difference between V_T/f_p before and V_T/f_p after physostigmine administration for each postdrug SPECT scan. To demonstrate the use of previously calculated nondisplaceable binding (V_{ND}/f_P) (*15*) and estimate specific radioligand binding (BP_f), we subtracted a fixed value (19.4 mL·cm^{-3}) of V_{ND}/f_P from V_T/f_P for each brain region and scan.

All statistical analyses were performed using SPSS, version 19.0 (IBM). Statistical significance was set at a P value of 0.05 or less, 2-tailed. Repeated measures of ANOVA (df = 5) were used to assess within-subject differences in pharmacokinetic parameters and mood variables before and after physostigmine administration. SD was calculated for all outcome variables (Table 1) and is represented as error bars in Figure 1.

TABLE 1
Outcome Values for Each Subject at Baseline and 2–4 Hours After Physostigmine Injection

Subject no.	fp at baseline	fp before physostigmine	fp after physostigmine*	fp at end of study	VT/fp at baseline				VT/fp after physostigmine*				BPf at baseline				BPf after physostigmine*			
					Thal	CB	Cort	Str	Thal	CB	Cort	Str	Thal	CB	Cort	Str	Thal	CB	Cort	Str
1	32.6%	37.0%	36.4%	39.2%	151.0	73.9	54.0	77.8	140.9	64.7	49.4	71.9	131.6	54.5	34.6	58.4	121.5	45.3	30.0	52.5
2	37.0%	36.1%	36.5%	37.5%	131.4	25.2	51.3	70.9	102.9	20.0	38.4	56.9	112.0	5.8	31.9	51.5	83.5	0.6	19.0	37.5
3	35.9%	34.7%	32.9%	28.6%	129.9	40.3	51.3	69.0	111.5	33.0	42.0	56.9	110.5	20.9	31.9	49.6	92.1	13.6	22.6	37.5
4	25.8%	25.0%	25.9%	34.2%	180.5	75.8	64.9	93.1	140.2	58.0	48.1	74.1	161.1	56.4	45.5	73.7	120.8	38.6	28.7	54.7
5	33.7%	37.4%	44.3%	47.3%	125.4	69.4	49.4	68.5	81.5	49.6	34.4	51.7	106.0	50.0	30.0	49.1	62.1	30.2	15.0	32.3
6	36.6%	35.4%	39.3%		111.1	55.6	40.9	65.1	111.0	55.4	40.0	67.8	91.7	36.2	21.5	45.7	91.6	36.0	20.6	48.4
Mean	33.6%	34.4%	35.9%	37.4%	138.2	56.7	52.0	74.1	114.7	46.8	42.0	63.2	118.8	37.3	32.6	54.7	95.3	27.4	22.6	43.8
SD	4.17%	4.65%	6.19%	6.87%	24.4	20.4	7.8	10.22	22.8	17.0	5.8	9.2	24.4	20.4	7.8	10.2	22.8	17.0	5.8	9.2

*Value at 2–4 h after physostigmine administration, at time of greatest displacement of radioligand by acetylcholine.
CB = cerebellum; Cort = mean cortex; Str = striatum; Thal = thalamus.
Final blood sample could not be drawn for subject 6.

FIGURE 1. First point in each graph represents baseline data obtained starting 6 h after beginning of tracer infusion, when state of equilibrium was achieved, and provided baseline specific binding. After completion of baseline scans, physostigmine was administered intravenously (1.0–1.5 mg over 1 h). At onset of physostigmine infusion, scanning was resumed for up to 9 h. Bars represent SEM. (A) Plasma ^{123}I-5-IA concentration (kBq/mL) (total parent) measured during ^{123}I-5-IA constant infusion in healthy volunteers. After physostigmine administration, there was significant 9% increase in mean plasma ^{123}I-5-IA concentration as compared with before physostigmine administration. (B) Tissue ^{123}I-5-IA concentration (kBq/cm³) in thalamus, striatum, cortex, and cerebellum measured during ^{123}I-5-IA constant infusion. We observed 7%–16% region-specific decrease in ^{123}I-5-IA tissue concentration after physostigmine challenge. (C) ^{123}I-5-IA V_T/f_p in thalamus, striatum, cortex, and cerebellum measured

during ^{123}I-5-IA constant infusion. V_T/f_p values measured after physostigmine infusion were significantly reduced (14%–18% region-specific), compared with baseline values. (D) ^{123}I-5-IA BP_f in thalamus, striatum, cortex, and cerebellum measured during ^{123}I-5-IA constant infusion. BP_f values measured after physostigmine infusion were significantly reduced (19%–36% region-specific), compared with baseline values.

RESULTS

Nonsmoking status was verified by negligible urine cotinine (0 ng/mL), plasma cotinine (<2ng/mL), and nicotine (<1.0 ng/mL) levels and exhaled carbon monoxide (0.7 ± 0.8 ppm). There were no significant differences in subjects' mood or anxiety before and after physostigmine administration ($P > 0.2$).

Administration of physostigmine did not significantly alter free fraction ($P > 0.2$) but resulted in significantly increased ^{123}I-5-IA total plasma parent activity for all subjects (9.1% ± 8.6%, $t = -2.56$, $P = 0.05$, 1 h after a challenge, stable thereafter; Fig. 1A) and significantly increased free parent activity (9.9% ± 7.7%, $t = -3.1$, $P = 0.03$) at 1 h after a challenge but not thereafter ($t = -1.2$, $P = 0.30$, 6 h after a challenge).

Equilibrium ^{123}I-5-IA binding (<5% change in receptor availability/h), was reached 6–8 h after injection (average change across subjects: 2.7% ± 1.7%/h in the thalamus, 3.6% ± 2.2%/h in the striatum, 2.5% ± 2.5%/h in the cortex, and 1.7% ± 1.6%/h in the cerebellum). ^{123}I-5-IA tissue concentration was reduced after physostigmine, with the peak reduction reached 2–4 h after a challenge (Fig. 1B), the same time point for the greatest decrease in ^{123}I-5-IA binding after nicotine administration (15,16). A reduction in ^{123}I-5-IA tissue concentration was observed in all brain regions 2–4 h after a challenge: thalamus, 7.8% ± 4.7%; striatum, 7.0% ± 0.9%; mean cortex, 12.7% ± 18.1%; and cerebellum, 16.5% ± 13.6%.

Administration of physostigmine significantly reduced the total volume of distribution of ^{123}I-5-IA at 2–4 h after

physostigmine administration. The peak average decrease in V_T/f_p was 18% ± 11% in cortical regions ($F_5 = 15.4$, $P = 0.01$), 17% ± 12% in the thalamus ($F_5 = 11.3$, $P = 0.02$), 14% ± 11% in the striatum ($F_5 = 11.0$, $P = 0.02$), and 17% ± 10% in the cerebellum ($F_5 = 10.4$, $P = 0.02$) (Figs. 1C and 2A).

Subtraction of V_{ND}/f_p revealed a greater percentage reduction in specific binding of ^{123}I-5-IA. The peak average decrease in BP_f was 29% ± 17% in cortical regions ($F_5 = 15.4$, $P = 0.01$), 19% ± 15% in the thalamus ($F_5 = 11.3$, $P = 0.02$), 19% ± 15% in the striatum ($F_5 = 11.0$, $P = 0.02$), and 36% ± 30% in the cerebellum ($F_5 = 10.4$, $P = 0.02$) (Figs. 1D and 2).

There was a significant decrease in pulse rate after physostigmine administration (12.3% ± 13.3%; $P = 0.08$) but no significant changes in blood pressure ($P > 0.7$).

DISCUSSION

We evaluated whether increases in extracellular levels of the endogenous neurotransmitter acetylcholine compete with ^{123}I-5-IA binding to β_2*-nAChRs. The goal of this study was to establish a novel paradigm to interrogate the cholinergic system in vivo in humans and to provide a more comprehensive interpretation of our (1,17) and other's (18) findings in populations with compromised cholinergic systems. Physostigmine administration resulted in a significant decrease in total ^{123}I-5-IA binding, suggesting that ^{123}I-5-IA is sensitive to extracellular acetylcholine levels. This reduction in ^{123}I-5-IA binding is similar to that achieved after smoking a cigarette from which the nicotine has been

FIGURE 2. (A–D) β_2^*-nAChR availability (V_T/f_P) before (hatched bars) and after (black bars) physostigmine injection for each subject. For thalamus (A), percentage displacement of 5-IA for subjects 1–6 was −7%, −22%, −14%, −22%, −35%, and −0%. For striatum (B), percentage displacement was −8%, −20%, −18%, −20%, −25%, and −4%. For cortex (C), percentage displacement was −9%, −25%, −18%, −26%, −30%, and −2%. For cerebellum (D), percentage displacement was −12%, −20%, −18%, −23%, −28%, and 0%. (E–H) BP_f before (hatched bars) and after (black bars) physostigmine injection for each subject. For thalamus (E), percentage displacement of 5-IA for subjects 1–6 was −8%, −25%, −17%, −25%, −41%, and 0%. For striatum (F), percentage displacement was −10%, −27%, −24%, −26%, −34%, and +5%. For cortex (G), percentage displacement was −13%, −40%, −29%, −36%, −50%, and −6%. For cerebellum (H), percentage displacement was −17%, −90%, −35%, −32%, −40%, and −1%.

removed ((*19*) and unpublished data from our group). Such cigarettes have only 0.05 mg of nicotine, equivalent to smoking about 1 puff from a regular cigarette. However, given that nicotine is a direct agonist at β_2^*-nAChRs and has high affinity for the receptor, and physostigmine-induced radioligand displacement has an indirect action, it is not surprising that administration of a high dose of physostigmine leads to displacement of ^{123}I-5-IA comparable to that from administration of 0.05 mg of nicotine.

The degree of reduction of ^{123}I-5-IA binding in the thalamus after a physostigmine challenge is in line with the findings of a previous study on nonhuman primates (*10*), although the amount of injected physostigmine was 10-fold less in the present human study. The similarity in the decrease of radioligand binding may be attributed to lower levels of acetylcholine release in anesthetized nonhuman primates than in conscious humans or to physiologic differences between species. The observed decrease in ^{123}I-5-IA binding here and in the previous study (*10*) was due to a combination of increases in ^{123}I-5-IA plasma concentration and a reduction in ^{123}I-5-IA tissue concentration. Thus, administration of physostigmine appears to alter radioligand distribution throughout the body, affecting tracer levels in the blood. Specifically, the increase in acetylcholine due to administration of physostigmine occurs throughout the body, and thus the peripheral nAChR binding sites previously available for binding of ^{123}I-5-IA are now also occupied by acetylcholine. The displacement of ^{123}I-5-IA in the body likely causes more free radioligand to circulate in the plasma. Thus, the tissue concentration alone is not an accurate measure for the evaluation of physostigmine-induced acetylcholine displacement of ^{123}I-5-IA, and total volume of distribution or specific ligand binding should be used in this paradigm.

There were several limitations to this study. First, physostigmine may have an allosteric effect on radioligand binding to β_2^*-nAChRs; however, physostigmine did not alter ^{123}I-5-IA binding in rat in vitro studies and had a significantly lower affinity for β_2^*-nAChR than did ^{123}I-5-IA (25,000 nM for physostigmine vs. 0.010 nM for ^{123}I-5-IA) (*4*). Thus, competition between physostigmine and ^{123}I-5-IA for binding to the receptor is not a likely explanation for the observed outcome of decreased ^{123}I-5-IA binding after physostigmine administration. Second, the use of V_{ND}/f_p obtained from a previous sample of control smokers may not be applicable to a study of nonsmokers. Further, the use of a fixed value for nondisplaceable binding across regions may not accurately reflect the observed regional differences in specific binding, especially for regions with lower levels of specific binding. Specifically, the change in thalamic V_T/f_p and BP_f was 16% and 19%, respectively, whereas the change in a lower-binding region (i.e., cerebellum) was 17% and 36%, respectively. Thus, BP_f values were reported with the purpose of showing how the estimate of V_{ND}/f_p may be used in future studies. Finally, the small sample size allows drawing only preliminary conclusions and limits examination of sex or age differences.

CONCLUSION

We developed a paradigm to interrogate the acetylcholine system in vivo in human subjects and observed a significant decrease in total binding of ^{123}I-5-IA after a physostigmine challenge, consistent with an increase in endogenous extracellular acetylcholine levels. This imaging tool may have enormous potential to facilitate the development of innovative medicines aimed at modulating the cholinergic system.

DISCLOSURE

ACKNOWLEDGMENTS

REFERENCES

1. Saricicek A, Esterlis I, Maloney K, et al. Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. *Am J Psychiatry.* 2012;169:851–859.

2. Abreo MA, Lin N-H, Garvey D, et al. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. *J Med Chem.* 1996;39:817–825.

3. Vaupel DB, Mukhin A, Kimes A, Horti A, Koren A, London E. *In vivo* studies with [^{125}I]5-IA 85380, a nicotinic acetylcholine receptor radioligand. *Neuroreport.* 1998;9:2311–2317.

4. Mukhin AG, Gundisch D, Horti A, et al. 5-iodo-A-85830, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. *Mol Pharmacol.* 2000; 57:642–649.

5. Fujita M, Tamagnan G, Zoghbi S, et al. Measurement of $\alpha_{4\beta2}$ nicotinic acetylcholine receptors with [^{123}I]5-I-A85830 SPECT. *J Nucl Med.* 2000;41:1552–1560.

6. Chefer S, Horti A, Lee K, et al. In vivo imaging of brain nicotinic acetylcholine receptors with 5-[^{123}I]iodo-A-85830 using single photon emission computed tomography. *Life Sci.* 1998;63:PL355–PL360.

7. Staley JK, van Dyck CH, Weinzimmer D, et al. Iodine-123-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. *J Nucl Med.* 2005;46:1466–1472.

8. Fujita M, Seibyl J, Vaupel D, et al. Whole body biodistribution, radiation-absorbed dose and brain SPET imaging with [^{123}I]5-I-A-85830 in healthy human subjects. *Eur J Nucl Med Mol Imaging.* 2002;29:183–190.

9. Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A. Acute effects of physostigmine and galantamine on the binding of [^{18}F]fluoro-A-85380: a PET study in monkeys. *Synapse.* 2005;56:217–221.

10. Fujita M, Al-Tikriti M, Tamagnan G, et al. Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [^{123}I]5-I-A-85380. *Synapse.* 2003;48:116–122.

11. Noori HR, Fliegel S, Brand I, Spanagel R. The impact of acetylcholinesterase inhibitors on the extracellular acetylcholine concentrations in the adult rat brain: a meta-analysis. *Synapse.* 2012;66:893–901.

12. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977;1:385–401.

13. Beck AT, Ward C, Mendelsohn M, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry.* 1961;4:561–571.

14. Spielberger C, Corsuch R, eds. *Manual for state-trait anxiety inventory.* Palo Alto CA: Consulting Psychologists Press; 1983.

15. Esterlis I, Cosgrove K, Batis J, et al. Quantification of smoking induced occupancy of β2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. *J Nucl Med.* 2010;51:1226–1233.

16. Esterlis I, Mitsis E, Batis J, et al. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. *Int J Neuropsychopharmacol.* 2011;14:389–398.

17. D'Souza DC, Esterlis I, Carbuto M, et al. Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. *Am J Psychiatry.* 2012; 169:326–334.

18. Ellis JR, Villemagne V, Nathan P, et al. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[^{18}F]fluoro-A-85380 PET study. *Neurobiol Learn Mem.* 2008;90:404–412.

19. Brody AL, Mandelkern M, Costello M, et al. Brain nicotinic cetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. *Int J Neuropsychopharmacol.* 2009;12:305–316.